Founder & CSO, Ori Biotech
Meet the founder
Modern medicine depends on small-molecule drugs and therapeutics, but Cell and Gene therapies (CGT) are poised to transform everything. By re-programming live tissue (often donor cells, or the patient’s own), they have the potential to create a one-shot cure for some of the world’s most severe diseases. But manufacturing CGTs is a challenge, which is where founder Farlan Veraitch comes in. Farlan is a leading academic in CGT biomanufacturing and has lead his team in pioneering a new development platform, designed to take the considerable cost out of CGT manufacture – and usher in a new age of medical care.
“It’s not just the money, you want all the other things that come along with those relationships.”
Why we invested
CGT will change the world, but first, costs have to come down. Currently, CGT account for the world’s most expensive treatments, with a single course costing anywhere up to £2m. Pioneering therapeutics need to be within reach for everyone, not just the lucky few, which is why we were so excited to meet Ori Biotech. Their proprietary platform leverages automation to remove the need for highly skilled human expertise, unlocking new possibilities in the development and manufacture of these future-shaping treatments.
Initial investment stage
More founder stories
Cleaning water for one billion people: Henrik Hagemann, CEO and co-founder
Sign up to our newsletter
Get the latest on the people, businesses and ideas that will change the world.
See our privacy notice